# Kanttekening bij coronaire plaquefenotypeveranderingen onder lipidenverlagende therapie

*geplaatst 2025-08-14 · Cholesterol · Atherosclerosis · doi https://www.atherosclerosis-journal.com/article/S0021-9150(25)01380-2/fulltext · https://hartvaat.nl/2025/08/14/kanttekening-bij-coronaire-plaquefenotypeveranderingen-onder-lipidenverlagende-t/*

Commentaar op de systematische review van Patti et al. over de relatie tussen lipidenverlagende therapie, coronaire plaquefenotypeveranderingen en cardiovasculaire events. Een overtuigende hypothese die voorzichtige interpretatie vraagt.

## English: Regarding “Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events”: a compelling hypothesis warranting cautious interpretation

This commentary provides a cautious interpretation of the systematic review by Patti et al. on lipid-lowering therapy-induced coronary plaque phenotype changes and their relationship with cardiovascular events. The hypothesis is compelling but requires careful methodological scrutiny.

## Abstract (original, from the publication)

We read with great interest the systematic review and meta-regression by Patti et al., which examines the relationship between lipid-lowering therapy (LLT)-induced changes in coronary plaque phenotype and major adverse cardiovascular events (MACE) [1]. The authors deserve recognition for this innovative analysis that attempts to quantify a biologically plausible yet elusive link. Their central finding - that each 10° decrease in maximum lipid arc measured by optical coherence tomography (OCT) correlates with a 39 % reduction in MACE risk - is compelling [1].

Auteurs: Artur Dziewierz, Beata Bobrowska, Renata Rajtar-Salwa

---
Bron: Atherosclerosis, https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01380-2/fulltext. Bijgewerkt 2026-07-03T13:25:07Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.